Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$35.15 - $51.45 $370,586 - $542,437
-10,543 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$13.25 - $17.05 $139,694 - $179,758
10,543
10,543 $174,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $762M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Harbourvest Partners LLC Portfolio

Follow Harbourvest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbourvest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Harbourvest Partners LLC with notifications on news.